“April 2017 : Intensification of the Company’s international development with the appointment of a new CEO : Mrs Nawal Ouzren”
“Sensorion aims to become a major player in the development of inner ear disease treatments of and thus fulfill unmet medical needs”
"Our mission is to develop innovative and targeted treatments for inner ear diseases with vertigo, tinnitus, hearing loss"
" Sensorion, has received “French Tech Pass” certification, and thus joins an exclusive circle of innovative French technology companies with substantial development potential"

Migraine-associated vertigo

Patients with migraine may have recurrent attacks of vertigo which vary in duration and severity (from a few seconds to 2-3 days).  These attacks may occur independently of the attack of migraine per se (in up to 50% of cases).

A retrospective epidemiogical study of 444 patients with migraine showed that vestibular migraine occurred in 17% of cases.  It is the second leading cause of vertigo in migraine patients after VPPB.  It occurs predominantly in women and the average age at the time of diagnosis is 43.7 years old.

The pathophysiological origin of migraine-associated vertigo has not been clearly established and may involve central (brain) or peripheral (vestibular) structures.

The treatments available are only symptomatic and are only intended to reduce the intensity and severity of the acute attacks.